1. Resources and Training
  2. Oncology
  3. Product resources and training
  4. Video: Professor Caroline Robert discusses the landmark 5-year data with Tafinlar (dabrafenib) + Mekinist (trametinib)

Prescribing information

 

Video: Professor Caroline Robert discusses the landmark 5-year data with Tafinlar (dabrafenib) + Mekinist (trametinib)

   

Professor Caroline Robert (Head of the Dermatology Unit at Gustave Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University) presents the latest 5-year data (pooled analysis) on the use of Tafinlar + Mekinist for the management of BRAF V600 metastatic melanoma.

Filmed June 2019.

The separate data from the COMBI-v and COMBI-d trials, on which this is based, can be viewed here.

 

 

 

Rate this content: 
No votes yet
TMC20-C004i May 2020
Oncology
Video
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]